The pharmaceutical company “Darnitsa” in 2020 received a net profit from the sale of products in the amount of UAH 4.3 billion, which is 33.7% more than a year earlier.
The chairman of the Darnitsa Group board of directors Dmytro Shymkiv said that about 10% of its income “Darnitsa” has directed to projects for the digital re-equipment of the company and the development of new drugs. He also said that over the past 5 years the plant has produced more than 45 new drugs, in the development of which Darnitsa Group has invested 35.3 million euros. The total amount invested in research and development over 10 years has reached about 200 million euros.
Shymkiv noted that the pharmaceutical concern continues the process of large-scale transformation, which began in 2019. After the rebranding, the company defined new strategic goals and values and changed its business philosophy.
The Darnitsa Group is now focused on building an international pharmaceutical brand, leading the way in the production of comprehensive generics and digitalizing 100 per cent of its business processes. Developing production and expanding the list of manufactured drugs, the management of the concern concentrates on the treatment of the most common diseases in Ukraine.
The plant manages to develop new drugs through cooperation with other international pharmaceutical companies, as well as through its own research. The Darnitsa Group annually spends more than 40% of the total investment money for the development of new drugs.
In addition to dozens of ready-made drugs on the pharmaceutical market, more than 50 Darnitsa drugs are at various stages of development. Shymkiv is confident that they will be registered by 2023. Darnitsa Group, unlike its competitors in Ukraine, specializes in the production of drugs for the prevention and treatment of diseases of the cardiovascular and nervous systems, as well as drugs that eliminate pain symptoms.
Dmytro Shymkiv explained what his optimistic statements regarding the development of the industry are based on. According to official data, the Ukrainian pharmaceutical market is entering the global pharmaceutical industry market as a rapidly developing one. In percentage, the rate of development of domestic pharmaceutics is on average 11% per year, which is three times higher than the growth rates of the Ukrainian economy.